AI Article Synopsis
- The study aimed to compare the effectiveness of infliximab, surgery, and a combination of both in treating perianal fistulas in patients with Crohn's disease.
- Patients were divided into three groups: those receiving only infliximab, those undergoing surgery, and those receiving both treatments.
- Results indicated that the combination of surgery and infliximab led to faster healing and a longer time before relapse compared to surgery or infliximab alone.
Article Abstract
Background: The aim of this study was to compare the outcomes of the management of perianal fistulas in Crohn disease between infliximab, surgery or a combination of surgery and infliximab.
Methods: We prospectively subdivided 35 consecutive patients with Crohn disease with complex perianal fistulas into 3 groups: 11 patients received infliximab (5 mg/kg intravenously at 0, 2 and 6 wk; group A), 10 underwent surgery (group B) and 14 received a combination of surgery and postoperative infliximab (group C). We evaluated the rate and time of healing of perianal fistulas, the rate of recurrences and time to relapse at a median follow-up of 18.8 (standard deviation [SD] 10.8, range 8-38) months.
Results: The time to healing of fistulas was significantly shorter among patients who received surgery and infliximab than among those who received surgery alone (p < 0.05) and was close to statistically shorter among those who received both treatments than among those who received infliximab alone (p = 0.06). Patients who received surgery and infliximab had a significantly longer mean time to relapse (p < 0.05) than those who received infliximab (mean 2.6 [SD 0.7] mo) or surgery alone (mean 3.6 [SD 0.5] mo).
Conclusion: We found better outcomes among patients who received a combination of surgery and infliximab therapy. These patients experienced a short time to healing of fistulas and significantly longer mean time to relapse of complex fistulas.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947112 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease.
BMC Gastroenterol
December 2024
Formerly Gastroenterology Department, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clínic de Barcelona, Barcelona, Spain.
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFClinical and Radiological Features of Perianal Fistula: An MRI-Based Study in Addis Ababa, Ethiopia.
Ethiop J Health Sci
October 2024
St. Paul Millennium Medical College, Department of Radiology, Addis Ababa, Ethiopia.
Background: Perianal fistula refers to an abnormal connection between the anal canal and the perianal skin or perineum. Magnetic Resonance Imaging (MRI) plays a crucial role in accurately characterizing perianal fistulas, which informs surgical strategies and helps minimize recurrence.
Methods: This cross-sectional study was conducted at a single diagnostic imaging center in Addis Ababa, utilizing retrospectively collected data from May 2023 to June 2024.
Intestinal Tuberculosis With Recurrent Gluteal Abscesses and Perianal Fistulas: A Case Report and Literature Review.
Cureus
December 2024
Pharmacology, Universidade Federal do Vale do São Francisco, Petrolina, BRA.
This case is relevant for describing a rare presentation of intestinal tuberculosis with perianal manifestations, complicated by abscesses and recurrent fistulas. The clinical manifestations mimicked Crohn's disease and other inflammatory conditions, making the diagnosis challenging and requiring a differentiated and meticulous diagnostic process. A 45-year-old male patient presented with a chronic abscess in the left buttock lasting for two years, characterized by spontaneous purulent drainage and multiple recurrences despite surgical and clinical treatments.
View Article and Find Full Text PDFExosomes derived from umbilical cord mesenchymal stem cells promote healing of complex perianal fistulas in rats.
Stem Cell Res Ther
December 2024
National Colorectal Disease CenterNanjing Hospital of Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, Jiangsu, People's Republic of China.
Background: Complex perianal fistulas, challenging to treat and prone to recurrence, often require surgical intervention that may cause fecal incontinence and lower quality of life due to large surgical wounds and potential sphincter damage. Human umbilical cord-derived MSCs (hUC-MSCs) and their exosomes (hUCMSCs-Exo) may promote wound healing.
Methods: This study assessed the efficacy, mechanisms, and safety of these exosomes in treating complex perianal fistulas in SD rats.
Long-term efficacy of mesenchymal stem cell treatment for complex perianal fistulas: A systematic review and meta-analysis.
Cent Eur J Immunol
November 2024
Department of Medical Security, The 908th Hospital of Chinese People's Liberation Army Joint Logistic Support Force, China.
Introduction: Complex perianal fistula, which is characterized by high occurrence and is difficult to treat with current surgical techniques, negatively affects the life quality of patients. Mesenchymal stem cells (MSCs) have emerged as a new innovative therapy in recent years due to their potent anti-inflammatory and immunomodulatory properties. Considering the high recurrence rate of complex perianal fistula, we performed this systematic review and meta-analysis to assess the long-term effects of MSCs on complex perianal fistula.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!